Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report

BACKGROUND: Sorafenib is a multi-targeted kinase inhibitor with a demonstrated activity in renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC), and it is currently used for the treatment of these pathologies. Ongoing clinical trials are studying its activity in other malignancies, such as...

Descripción completa

Detalles Bibliográficos
Autores principales: Casadei Gardini, Andrea, Chiadini, Elisa, Faloppi, Luca, Marisi, Giorgia, Delmonte, Angelo, Scartozzi, Mario, Loretelli, Cristian, Lucchesi, Alessandro, Oboldi, Devil, Dubini, Alessandra, Frassineti, Giovanni Luca, Ulivi, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937544/
https://www.ncbi.nlm.nih.gov/pubmed/27388325
http://dx.doi.org/10.1186/s12885-016-2463-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937544/
https://www.ncbi.nlm.nih.gov/pubmed/27388325
http://dx.doi.org/10.1186/s12885-016-2463-2

Ejemplares similares